Report Subject - Medical Affairs - Page 1

Learn More Virtual Clinical Trials: The future of drug development?

How viable are virtual clinical trials as a model for conducting clinical research? With our deepening understanding of disease and ever more targeted therapies, slow and costly traditional clinical trials alone are no...

Compare
Learn More Artificial Intelligence and Machine Learning: Applications in Pharma

Where can Artificial Intelligence and Machine Learning really drive change in pharma's business? Artificial Intelligence (AI) and Machine Learning (ML) have the potential to unlock new insights and massively improve...

Compare
Learn More Medical-grade Wearable Technology: Applications and implications for pharma

Leveraging clinical wearables and digiceuticals to gain competitive advantage From smart wristbands and glasses to tiny sensors in pills, the latest advances in medical-grade technology are unlocking new opportunities...

Compare
Learn More Voice Assistants and Medical Chatbots in Healthcare

Voice activated technology: What are the potential benefits for pharma? The use of voice-controlled assistants (VCAs) such as Apple's Siri and Amazon's Alexa are familiar to many of us in our daily lives. But how might...

Compare
Learn More Gene Therapy: Commercial Opportunities and Challenges for Pharma

As gene therapies for major diseases accelerate from the development pipeline, how can pharma exploit near-term opportunities and protect its business going forward? As gene therapies for major diseases accelerate from...

Compare
Learn More Digital Therapeutics: Taking digital health to a new level

The Digital Therapeutics field is exploding: what does pharma need to know - and do - to get on board? Evidence-based and reimbursed digital therapeutics (DTx) are now part of the health delivery landscape. They hold...

Compare
Learn More Blockchain: Transformational change for Pharma?

Is blockchain really the technology that can revolutionise pharma's business? Rapidly developing Blockchain technology can deliver transparent, secure and reliable data sharing. It also has the prospect of streamlining...

Compare
Learn More The Impact of Nanomedicine in the Pharma Industry

Can nanomedicines really offer pharma a compelling alternative approach to precision medicines? Delivering accurate diagnosis for clinicians, safer medicines for patients and lower costs through reduced waste and costly...

Compare
Learn More Medical Affairs in Emerging Markets

How can medical affairs capability be enhanced to unlock the Brazilian, Russian, Indian and Chinese pharma markets? The pharma markets of Brazil, Russia, India and China (BRIC) are becoming increasingly complex with...

Compare
Learn More Orphan Drug Launch Strategies: Case Studies

Achieving commercial success for orphan drugs requires specific strategies to be adopted, not least because market barriers are very different from those encountered when launching more common disease therapies. Lack of...

Compare
Learn More Medical Affairs Reputations: Asthma/COPD (EU5) 2017

How well does your asthma/COPD medical affairs team performance compare with the rest? According to this latest survey of 150 pulmonologists and primary care physicians across the EU5 (UK, France, Germany, Italy and...

Compare
Learn More Medical Affairs Reputations: Asthma/COPD (US) 2017

How well does your asthma/COPD medical affairs team performance compare with the rest? According to this latest survey of 100 US pulmonologists and primary care physicians, the performance of asthma/COPD medical affairs...

Compare
Learn More MSL stakeholder engagement: meeting expectations

MSL Stakeholder Engagement–Meeting Expectations In this report, FirstWord identifies practical solutions to the stakeholder engagement challenges faced by medical science liaisons (MSLs) teams in 2017. Discover...

Compare
Learn More Charting MSL Activity and Performance (2017)

A unique survey-based report providing key insights and actionable intelligence about MSL activity and performance. Charting MSL Activity and Performance (2017) distils key findings from one of the most comprehensive...

Compare
Learn More Medical Affairs in Orphan Drugs

Orphan drugs: Is your medical affairs team leading the fray or lagging behind? Traditional commercial models simply don’t work for orphan drugs, not least because the physician and patient populations are so...

Compare
Learn More The Future of Medical Affairs

What are the future opportunities and challenges for medical affairs? As the interface between companies and KOLs, HCPs, payers and patients, medical affairs has grown rapidly in importance. And demands are set to...

Compare

Browse by